CHICAGO — Semaglutide, a glucagon-like peptide (GLP-1) receptor agonist, has shown convincing benefits in yet another population: patients with peripheral arterial disease (PAD). In the STRIDE ...

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with symptomatic peripheral ... ankle brachial index really suggests a direct ...

Ozempic improved walking distance in patients with diabetes and peripheral artery disease at 1 year ... intermittent claudication and an ankle-brachial index of 0.9 or less or a toe-brachial ...

We find it helpful to mark the location of each pedal artery with a black ... left brachial systolic BPs. An ABI of 0.90 or less is PAD by definition, though disease may be present with ABI ...

CHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building its positions in peripheral artery ... an ankle-brachial index ≤0 ...

Limus-based devices, rather than being a substitute for paclitaxel as they were once seen, are coming of age in peripheral ...

A case-based discussion navigates the decision-making process for a patient with chronic limb-threatening ischemia with poor ...

Accurate vascular assessment is critical in wound care. ABPI testing, though historically underused, is a cornerstone of ...

Heart disease ... vascular disease as cardiac disease. “We’ll know how to order stress tests, echos, EKGs, etc., but we’re also supposed to know how to interpret an ankle brachial index ...

AURORA, CO / ACCESS Newswire / March 29, 2025 / A novel study of a semaglutide, a glucagon-like peptide-1 (GLP-1) agonist used to treat type 2 diabetes, obesity and cardiovascular disease ... increase ...